New drug duo aims to tackle stubborn breast cancer before surgery
NCT ID NCT05675579
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving sacituzumab govitecan and pembrolizumab before surgery can help control early-stage triple-negative breast cancer that didn't respond to initial chemotherapy and immunotherapy. The study enrolls 27 adults with specific tumor types. The main goal is to check safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan and pembrolizumab (given by IV)
What this could lead to
If it works, this could offer a new treatment option for people with early-stage triple-negative breast cancer that hasn't responded to standard chemotherapy and immunotherapy.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination may cause side effects and may not improve outcomes enough to change standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States